[
    [
        {
            "time": "",
            "original_text": "热情高涨！10股获百家机构扎堆调研，24家百亿私募现身（附名单）",
            "features": {
                "keywords": [
                    "热情高涨",
                    "机构调研",
                    "百亿私募"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "私募基金"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "热情高涨！10股获百家机构扎堆调研，24家百亿私募现身（附名单）",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "抗击新冠疫情系列报告之五：新冠疫苗研发跟踪 需求与成本分析",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "需求",
                    "成本分析"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "抗击新冠疫情系列报告之五：新冠疫苗研发跟踪 需求与成本分析",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【国信医药】全面国际化，迎接“十四五”（2021年度策略）",
            "features": {
                "keywords": [
                    "国信医药",
                    "国际化",
                    "十四五"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "国际化"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国信医药】全面国际化，迎接“十四五”（2021年度策略）",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        }
    ]
]